Biogen (BIIB) Tops Q1 EPS by 6c; cuts guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $196.58 -1.05%
Revenue Growth %: -6.5%
Financial Fact:
Income tax expense: 337M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -6.5%
Financial Fact:
Income tax expense: 337M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.02, $0.06 better than the analyst estimate of $2.96. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.23 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $14.50-$15.50, versus the consensus of $15.20.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
- JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
- Barclays Reinstates EQT AB (EQT:SS) (EQBBF) at Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
